Search the Newsreel

Heron Therapeutics Q2 2026 Loss Widens 50.0% Beyond Estimates

Heron Therapeutics (NASDAQ: HRTX) reported a Q2 2026 diluted loss of $0.03 per share, exceeding analyst estimates by 50.0%, and revenue of $37.7 million, which fell 10.7% short of expectations. The company experienced a 1.6% stock drop as its largest segment, Oncology, saw a …

Heron outlines covenants through 2027 and pro forma cash of $24.3M after September debt payment

Earnings Call Insights: Heron Therapeutics (HRTX) Q2 2026 MANAGEMENT VIEW * “Net revenue for the quarter was $37.7 million… it is below what we expected of ourselves,” said (CEO & Director Craig Collard), adding that “CINVANTI sales were up compared to Q1 in a …

Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook

Heron Therapeutics has withdrawn its full-year 2026 financial guidance due to uncertainty surrounding potential generic competition for its key product, CINVANTI, following a recent court decision. The company's second-quarter revenue was below expectations, with strong growth in Acute Care revenue (ZYNRELEF and APONVIE) not …

Heron Therapeutics earnings missed by $0.02, revenue fell short of estimates

Heron Therapeutics (NASDAQ: HRTX) reported a second-quarter EPS of $-0.030, missing analyst estimates by $0.02, and revenue of $37.67M, falling short of the consensus estimate of $42.13M. The company's stock has seen significant declines over the past 3 and 12 months. InvestingPro rates Heron …

Earnings call transcript: Heron Therapeutics misses Q2 2026 revenue forecast

Heron Therapeutics reported Q2 2026 revenue of $37.7 million, missing the forecast of $42.13 million, leading to an 18.74% drop in stock price. The company withdrew its full-year guidance due to uncertainty surrounding its CINVANTI franchise patent ruling, changes in spending, and a review …

Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates

Heron Therapeutics (HRTX) reported a Q2 loss of $0.03 per share, missing the Zacks Consensus Estimate of a $0.02 loss and representing an earnings surprise of -50.00%. The company also failed to meet revenue estimates, posting $37.67 million against an expectation of $42.39 million. …

Heron Therapeutics reports Q2 2026 revenue $37.7M, withdraws 2026 guidance after patent ruling

Heron Therapeutics announced Q2 2026 net revenue of $37.7 million and a net loss of $5.5 million, ending the quarter with $42.7 million in cash. The company withdrew its full-year 2026 guidance following an unfavorable Delaware court decision impacting CINVANTI patents and is evaluating …

Heron Therapeutics Announces Second Quarter 2026 Financial Results

Heron Therapeutics announced its Q2 2026 financial results, with net revenue of $37.7 million, a 9% increase from Q1 2026. The company saw significant year-over-year growth in ZYNRELEF® (35%) and APONVIE® (74%) net revenue, but withdrew its full-year 2026 financial guidance due to uncertainty …

Heron Therapeutics Q2 Revenue Rises To $37.7 Million

Heron Therapeutics reported a 1.3% year-over-year increase in Q2 2026 net revenue, reaching $37.7 million, with acute care and specific product revenues showing significant growth, although oncology revenue declined. The company posted a net loss of $5.5 million and withdrew its full-year 2026 guidance. …

Heron Therapeutics: Q2 Earnings Snapshot

Heron Therapeutics Inc. (HRTX) reported a second-quarter loss of $5.5 million, translating to 3 cents per share. The pharmaceutical company, based in Cary, North Carolina, also announced revenues of $37.7 million for the period. This financial summary was generated using data from Zacks Investment …

Wall Street Zen Upgrades Heron Therapeutics (NASDAQ:HRTX) to Sell

Wall Street Zen has upgraded Heron Therapeutics (NASDAQ: HRTX) to a "sell" rating, contrasting with the broader analyst consensus of "hold." The biotechnology company recently missed quarterly earnings and revenue expectations, reporting a loss of $0.04 per share against a $0.03 consensus loss and …

Heron Therapeutics Inc (HRTX) News, Articles, Events & Latest Updates

This article provides recent news and updates for Heron Therapeutics Inc (HRTX), including its Q2 2026 earnings report where it missed revenue estimates and its Q1 2026 report showing a loss and lagging revenue. The company's stock was also added to Zacks' "Strong Sell" …

Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of "Hold" from Analysts

Heron Therapeutics (NASDAQ:HRTX) has received an average "Hold" recommendation from analysts, with a 12-month average price target of $2.50. The company recently reported a quarterly loss of $0.04 per share and revenue of $34.71 million, both below analyst expectations. Institutional investors and hedge funds …

Heron Therapeutics (NASDAQ:HRTX) Upgraded to Hold at Zacks Research

Zacks Research has upgraded Heron Therapeutics (NASDAQ:HRTX) from a "strong sell" to a "hold" rating, aligning with the broader analyst consensus. The biotechnology company, with a market capitalization of $96.8 million, recently missed its quarterly earnings and revenue estimates. Despite this, institutional investors hold …

Heron Therapeutics (HRTX) Projected to Post Quarterly Earnings on Monday

Heron Therapeutics (HRTX) is expected to report its Q2 2026 earnings before market open on Monday, August 10th, with analysts projecting a loss of $0.02 per share and revenue of $42.19 million. The company missed expectations in the previous quarter, reporting a $0.04-per-share loss …

Heron Therapeutics, Inc. Revenue Breakdown – NASDAQ:HRTX

Heron Therapeutics, Inc. (NASDAQ:HRTX) generated $154.90 million USD in revenue last year, primarily from its Therapeutic Innovations segment. This represents an increase from $144.28 million USD in the previous year. All reported revenue for the company originated from the United States.

Heron Therapeutics Inc (HRTX) Institutional Confidence

Heron Therapeutics Inc (HRTX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The company's institutional shareholding proportion is 90.02%, showing a quarter-over-quarter increase of 5.58%. James Simons is the largest institutional shareholder, holding 0.91% of …

Heron Therapeutics Inc (HRTX) Financial Health: Profitability & Balance Sheet Analysis

Heron Therapeutics Inc (HRTX) currently holds a financial score of 7.51, ranking 112 out of 385 in the Biotechnology & Medical Research industry, indicating a weak financial status despite high operating efficiency. The company's latest quarterly revenue decreased by 10.78% year-over-year to $34.71 million, …

Heron Therapeutics Inc Revenue Breakdown – BX:AXD2

Heron Therapeutics Inc (BX:AXD2) generated 122.80 million CHF in revenue last year, primarily from its Therapeutic Innovations segment, which slightly decreased from 131.04 million CHF the previous year. The United States was the largest contributor to this revenue.

Heron Therapeutics Schedules Aug. 10 Webcast for Q2 Results

Heron Therapeutics (Nasdaq: HRTX) will report its second-quarter 2026 financial results on Monday, August 10, 2026, at 8:30 a.m. ET. The company will host a conference call and live webcast to discuss these results and recent business highlights. Investors can access the event via …

Heron Therapeutics Inc (HRTX) Cash Flow

This article provides a detailed cash flow statement for Heron Therapeutics Inc (HRTX), including quarterly and annual data for operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flow and how to interpret them for HRTX. Investors …

Heron Therapeutics Inc (AXD2) Q4 2022 Earnings Report - Results, Call & Slides

Heron Therapeutics Inc (AXD2) announced its Q4 2022 earnings, reporting an EPS of -€0.15 on revenue of €26.37M, beating analyst consensus for both metrics. The company's revenue grew 45.38% year-over-year. The next earnings date is estimated for August 11, 2026.

HRTX|Heron Therapeutics Inc|Price:0.456|Chg%:-0.003

Heron Therapeutics Inc. (HRTX) is a commercial-stage biotechnology company trading at $0.456, experiencing a slight decline of 0.70%. The company is focused on improving patient lives through therapeutic innovations, particularly in acute care and oncology. Despite strong institutional ownership and high growth in revenue …

Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Report - Results, Call & Slides

Heron Therapeutics (HRTX) reported strong Q1 2024 earnings, beating both EPS and revenue expectations. The company recorded an actual EPS of -$0.02 against a consensus of -$0.07, and revenue of $34.67 million, surpassing the expected $32.98 million. The report also highlights a significant year-over-year …

Heron Therapeutics (HRTX) Quarterly Loss Revives Dilution Fears And Tests Profitability Narrative

Heron Therapeuti earnings missed by $0.02, revenue fell short of estimates

Earnings call transcript: Heron Therapeutics Q1 2026 results miss forecasts, stock drops

Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates

Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for

HERON THERAPEUTICS ($HRTX) Releases Q4 2025 Earnings

Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Market Sentiment Around Loss-Making Heron Therapeutics, Inc. (NASDAQ:HRTX)

Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported, And Analysts Assigned A US$4.50 Price Target